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The recent increase in azole-resistant Aspergillus fumiga-
tus is a global concern. Identifying the mutations that confer 
azole resistance is essential for developing novel meth-
ods for prompt diagnosis and effective drug treatment. We 
screened A. fumigatus clinical isolates for novel mutations 
conferring azole resistance. We compared the genomic se-
quences of susceptible and resistant isolates without muta-
tions in cyp51A (non-cyp51A) and found mutations in hmg1 
and erg6 involved in ergosterol biosynthesis. We also found 
the novel mutations in these genes in azole-resistant iso-
lates with different genetic backgrounds. The resistant iso-
lates with mutations in hmg1 showed increased intracellular 
ergosterol levels compared with susceptible isolates. This 
finding supports the concept that the ergosterol level is a 
determinant for resistance to any class of azoles. Multiple 
isolates with increased resistance to azole possessed a mu-
tation in hmg1, indicating that this mutation is widely present 
in non-cyp51A azole-resistant A. fumigatus.
Aspergillus fumigatus is known as an opportunistic pathogen of fungal infection and causes a high mor-
tality rate among immunosuppressed patients (1,2). Azole 
drugs are considered the first-line therapy in various dis-
eases of aspergillosis. The recent increase of azole drug-
resistant A. fumigatus is a major limitation of therapeutic 
strategies in clinical settings and a concern throughout the 
world (3). Most azole-resistant strains harbor a mutation in 
the cyp51A gene, encoding a target protein for azole drugs 
(4). The point-mutated Cyp51A has lower binding affinity 
to azole drugs, causing azole resistance in these strains (5). 
The amino acid substitution in Cyp51A protein is thought 
to occur during azole therapy inside hosts. In addition, 34 
bp or 46 bp of tandem repeats in the promoter region of cy-
p51A cause azole resistance (6). The high incidence of such 
tandem repeat–type resistant strains is alarming (7), and it 
is widely accepted that the tandem repeat–type resistant 
mechanism is derived from exposure to azole fungicides in 
the environment (8). Whereas such cyp51A-related azole-
resistant strains have been reported frequently in the past 
10 years, strains without any mutation in the cyp51A gene 
showing low susceptibility to azole drugs have, to some 
extent, been isolated (9). Which mutation leads to azole 
resistance has thus far been determined in only a few non-
cyp51A azole-resistant strains. For a deeper and broader 
understanding of the molecular mechanisms underlying re-
sistance to antifungal drugs, the non-cyp51A azole-resistant 
strains have become the focus of attention.
The cdr1B gene, encoding an ABC transporter, plays 
a role in azole resistance. Deletion of the gene resulted 
in azole-sensitive phenotypes (10), and an azole-resistant 
strain with constitutive expression of cdr1B has been iso-
lated from a patient (11). The expression of cdr1B is depen-
dent on AtrR, a recently characterized transcriptional factor 
(12), but the reason for the constitutive expression remains 
unclear. A strain showing azole resistance with a mutation 
(P88L) in the hapE gene has also been isolated; the muta-
tion was discovered by genome comparison between azole-
resistant strains and corresponding susceptible strains (13). 
A recent study showed that HapE forms a CCAAT binding 
complex, which plays a role in the negative regulation of 
cyp51A expression. The amino acid substitution in HapE 
(P88L) resulted in increased cyp51A expression and conse-
quent azole resistance (14). 
These studies provided convincing evidence of the 
roles of Cdr1B and HapE in azole adaptation in A. fumiga-
tus. However, each of these mutations has been reported 
only once in clinical isolates. Furthermore, a large portion 
of the non-cyp51A azole-resistant A. fumigatus strains have 
yet to be investigated to determine which genes and muta-
tions could be responsible for azole resistance. To fill a gap 
in our understanding of the mechanism for azole resistance 
in the non-cyp51A strains, we searched for mutations in a 
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series of isolates derived from a single patient in Japan who 
had chronic pulmonary aspergillosis (CPA) and isolates 
from other patients with and without azole resistance. 
Materials and Methods
 A. fumigatus Strains
All clinical isolates used in this study were preserved at 
Chiba University Medical Mycology Research Center 
(Chiba City, Japan). We obtained 19 isolates from a patient 
at hospital C who had CPA (Tables 1, 2), 3 isolates (IFM 
63768, IFM 63666, and IFM 63772) from another CPA pa-
tient at hospital C on different days, and additional isolates 
from 3 other patients with CPA at different hospitals (IFM 
62140 at hospital K, IFM 64258 at hospital I, and IFM 
64303 at hospital T). We also obtained 16 azole-susceptible 
clinical isolates (Table 3) from respiratory samples (sputa, 
pleural effusion, lung tissues, or bronchoalveolar fluids) or 
pus from a subcutaneous abscess from patients with asper-
gillosis in various hospitals in Japan.
Microsatellite Genotyping
For genotyping, we PCR amplified and sequenced 6 loci 
of ≈400 bp from all of the isolates as described previously 
(15). We counted the repeat numbers of each region (2A, 
2B, 2C, 3A, 3B, 3C, 4A, 4B, and 4C) from the sequence.
Antifungal Susceptibility Testing
We performed antifungal susceptibility testing as described 
previously (16). In brief, we performed tests in triplicate 
using amphotericin B (AMPH), itraconazole (ITCZ), vori-
conazole (VRCZ), and posaconazole (PSCZ) in RPMI 
1640 medium (pH 7.0) at 35°C, according to the Clini-
cal and Laboratory Standards Institute reference method 
for broth microdilution (https://clsi.org/standards/products/
microbiology/documents/m38), with partial modifications 
using the dried plate for antifungal susceptibility testing 
(Eiken Chemicals, Tokyo, Japan).
Sequencing cyp51A, erg6, and hmg1 Genes
To detect mutations in cyp51A, erg6, and hmg1 genes, 
we performed PCR amplification and sequenced these re-
gions using appropriately designed primers (online Tech-
nical Appendix Table 1, https://wwwnc.cdc.gov/EID/
article/24/10/18-0730-Techapp1.pdf). We performed se-
quence variant detection by comparison with reference se-
quences from GenBank and Fungi DB (http://fungidb.org/
fungidb/) (GenBank accession no. AF338659 for cyp51A, 
Fungi DB accession nos. AFUB_020770 for hmg1, and 
AFUB_099400 for erg6).
Whole-Genome Sequencing
We performed whole-genome sequencing by using next-
generation methods as described previously (15). In brief, 
we extracted genome DNA from overnight-cultured my-
celia by DNeasy Plant Mini Kit (QIAGEN, Hilden, Ger-
many) or by phenol-chloroform extraction and Nucleobond 
AXG column (TaKaRa, Kusatsu, Japan) with Nucleobond 
Buffer Set III (TaKaRa). For analyzing IFM 60814 and 
IFM 63240, we prepared a fragmented DNA library by 
using a Nextera DNA sample preparation kit according to 
the manufacturer’s instructions (Illumina, San Diego, CA). 
The mean length of the libraries was 376–674 bp. We per-
formed sequencing in a paired-end 2 × 150 bp mode on a 
MiSeq system (Illumina). For analyzing IFM 63666 and 
IFM 63768, we prepared a fragmented DNA library using 
KAPA HyperPlus Library Preparation Kit (Kapa Biosys-
tems, Wilmington, MA) according to the manufacturer’s 
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Table 1. Number of short tandem repeats in Aspergillus fumigatus isolates from a single patient in Japan* 
Isolate 
IFM no.  
Date isolated  
(isolate set) 
Short tandem repeats 
2A 2B 2C 3A 3B 3C 4A 4B 4C 
60814 2011 Sep (1st) 21 20 16 39 13 24 10 12 8 
62916 2014 Sep (2nd) 21 20 16 39 13 24 10 12 8 
63240 2014 Nov (3rd) 21 20 16 39 13 25 10 12 8 
63241  21 20 16 39 13 25 10 12 8 
63242  21 20 16 39 13 25 10 12 8 
63243  21 20 16 39 13 25 10 12 8 
63248 2015 Jan (4th) 21 20 16 39 13 24 10 12 8 
63249  21 20 16 39 13 25 10 12 8 
63537 2015 Jul (5th) 21 20 16 39 13 24 10 12 8 
63594 2015 Sep (6th) 21 20 16 39 13 24 10 12 8 
63595  21 20 16 39 13 24 10 12 8 
63596  21 20 16 39 13 24 10 12 8 
63711 2015 Dec (7th) 21 20 16 39 13 24 10 12 8 
63712  21 20 16 39 13 24 10 12 8 
63713  21 20 16 39 13 24 10 12 8 
63714  21 20 16 39 13 24 10 12 8 
64138 2016 Apr (8th) 21 20 16 39 13 24 10 12 8 
64139 21 20 16 39 13 24 10 12 8 
64173 2016 May (9th) 21 20 16 39 13 24 10 12 8 
*IFM, Institute of Food Microbiology (now Medical Mycology Research Center), Chiba University, Chiba City, Japan. 
 
Azole-Resistant Aspergillus fumigatus 
instructions. We performed sequencing in a paired-end 2 × 
300 bp mode on a MiSeq system (Illumina).
Single-Nucleotide Variant Detection
To search for single-nucleotide polymorphisms (SNPs) be-
tween IFM 60814, the first isolate obtained, and IFM 63240–
63243, the third set of isolates, we performed read-mapping 
and SNP detection using CLC Genomics Workbench (CLC 
bio, Aarhus, Denmark). In brief, we trimmed the reads from 
each isolate and mapped them to the Af293 reference genome. 
By comparing them with the Af293 sequence, we detected 
sites with SNPs in IFM 60814, IFM 63240, IFM 63241, IFM 
63242, and IFM 63243. We also compared the sets of varied 
sites between IFM 60814  and IFM 63240–63243. We con-
sidered the unique sites common in IFM 63240–63243 to be 
the SNPs between the first isolate and the third set of isolates.
We cleaned the read datasets of IFM 63666 and 
IFM 63768 using Trimmomatic version 0.33 (17). We 
trimmed reads to generate de novo assembly of the draft 
genome of IFM 63666 using Platanus version 1.2. 4 with 
default parameters (18). We performed annotation of all 
predicted open reading frames of the draft genome using 
AUGUSTUS version 2.5.5 (19). For nucleotide differ-
ences between IFM 63666 and IFM 63768, we mapped 
the trimmed reads of IFM 63768 to the draft genome 
of IFM 63666 using SMALT version 0.7.6 (http://www.
sanger.ac.uk/science/tools/smalt-0). We identified SNPs 
using SAMtools version 0.1.19–44428cd (20) and fil-
tered with >10-fold coverage, >30 mapping quality, 
and 75% consensus using in-house scripts (21,22). We 
annotated the functional effect of SNPs with SnpEff  
version 4.1l (23).
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Gene with mutation 
AMPH ITCZ VRCZ PSCZ Cyp51 Hmg1 Erg6 
60814 2001 Sep (1st) <0.015 0.5 0.5 0.5 1  – – – 
62916 2014 Sep (2nd) <0.015 0.5 >8 >8 8  G448S S269F E49K 
63240 2014 Nov (3rd) <0.015 1 >8 >8 4  – S269F A350T 
63241  <0.015 0.5 >8 >8 8  – S269F A350T 
63242  <0.015 1 >8 >8 8  – S269F A350T 
63243  <0.015 1 >8 >8 8  – S269F A350T 
63248 Jan 2015 (4th) ND ND ND ND ND  – S269F E49K 
63249  <0.015 1 4 8 8  G448S S269F E49K 
63537 2015 Jul (5th) <0.015 1 >8 8 8  – S269F A350T 
63594 2015 Sep (6th) <0.015 1 >8 >8 8  – S269F A350T 
63595  <0.015 1 >8 >8 >8  G448S S269F E49K 
63596  <0.015 1 >8 >8 8  – S269F A350T 
63711 2015 Dec (7th) ND ND ND ND ND  – S269F E49K 
63712  ND ND ND ND ND  G448S S269F E49K 
63713  ND ND ND ND ND  G448S S269F E49K 
63714  <0.015 1 >8 8 4  – S269F E49K 
64138 2016 Apr (8th) ND ND ND ND ND  – S269F E49K 
64139 ND ND ND ND ND  G448S S269F E49K 
64173 2016 May (9th) <0.015 0.5 >8 8 4  – S269F A350T 
*AMPH, amphotericin B; IFM, Institute of Food Microbiology (now Medical Mycology Research Center), Chiba University, Chiba City, Japan; ITCZ, 
itraconazole; MCFG, micafungin; MEC, minimal effective concentration; ND, not determined; PSCZ, posaconazole; VRCZ, voriconazole; –, no mutation. 
 
 





MIC, mg/L  Gene with mutation   Short tandem repeats 
AMPH ITCZ VRCZ hmg1 erg6 3A 3B 3C 4A 4B 4C 
49435 <0.015 1 0.25 0.25  – –  52 17 20 10 11 11 
50268 <0.015 0.5 0.25 0.125  – –  14 10 11 13 9 10 
50669 <0.015 1 0.5 0.25  – –  12 18 20 16 9 5 
50999 <0.015 1 0.5 0.5  – –  33 12 37 11 9 5 
51748 <0.015 0.5 0.125 0.125  – –  26 11 29 25 10 8 
51977 <0.015 1 0.25 0.25  – –  25 9 7 12 11 17 
57130 <0.015 1 0.25 0.125  – –  47 21 19 10 11 5 
58402 <0.015 1 0.5 0.5  – –  27 10 5 9 9 5 
60065 <0.015 1 1 0.5  – –  15 17 17 17 16 10 
60516 <0.015 1 1 1  – –  22 11 7 16 11 8 
60901 <0.015 1 0.5 0.5  H564Y –  23 28 21 8 11 10 
61572 <0.015 1 0.5 0.5  – –  59 19 7 10 14 8 
61960 <0.015 1 0.5 0.5  – –  27 11 35 10 9 10 
62674 <0.015 1 1 2  – –  35 10 14 16 10 10 
62709 <0.015 1 0.5 0.5  – –  38 18 7 10 14 9 
62821 <0.015 1 0.5 0.25  – –  37 14 7 10 11 10 
*AMPH, amphotericin B; IFM, Institute of Food Microbiology (now Medical Mycology Research Center), Chiba University, Chiba City, Japan; ITCZ, 
itraconazole; MCFG, Micafungin; MEC, minimal effective concentration; VRCZ, voriconazole; –, no mutation. 
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Growth Test for Ergosterol-Related Inhibitors
We performed disk diffusion assay using the protocol de-
scribed by Qiao et al. (24). We spread a 200-µL suspension 
(1 × 106 conidia/mL) of each of the tested isolates uniform-
ly onto YGA (glucose 2%, yeast extract 0.5%, agar 2%, 
trace element). We impregnated blank paper disks 8 mm in 
diameter with 2.5 µg amphotericin B, 100 µg nystatin, or 
40 µg lovastatin and placed the disks onto the center of the 
inoculated agar plates. We incubated the plates at 37°C and 
measured the diameters of the zones of inhibition 48 hours 
later. We performed each assay 3 times and calculated the 
mean diameter.
Ergosterol Quantification
We conducted total ergosterol extraction using the pro-
tocol described by Arthington-Skaggs et al. and Alcazar-
Fuolietal (25,26). We cultured A. fumigatus isolates for 20 
h in glucose minimal medium. We harvested mycelia by 
filtration, washed them with sterile water, and then dried 
and weighed them. We added 3 mL of 25% alcoholic po-
tassium hydroxide solution to dried mycelia and mixed 
for 1 min, then incubated the mixture in an 80°C water 
bath for 1 h. After incubation, we added water and 3 mL 
of pentane and mixed for 3 min. We transferred the upper 
pentane layer to a clean glass tube for evaporation. We 
dissolved the dried samples in 1 mL of methanol and fil-
tered it through a 0.22-µm pore size membrane filter. We 
analyzed ergosterol content using the Shimadzu LC-20A 
system (Shimadzu, Kyoto, Japan) with COSMOSIL 5C18-
MS-II column (4.6 mm ID × 100 mm; Nacalai Tesque, 
Kyoto, Japan). We established a flow rate of 1 mL/min of 
acetonitrile to water (95:5 vol/vol). We used peak areas 
and heights recorded at a 254-nm wavelength in an RF-
20Axs (Shimadzu) for quantification, expressing total er-
gosterol concentration as µg ergosterol per mg fungal dry 
weight. We repeated each experiment >3 times.
Construction of Mutant Erg6, Hmg1, and  
Cyp51A Expressed Strains
To construct transformants expressing erg6, hmg1, or 
cyp51A with the mutation, we cloned the alleles using 
the shuttle vector pPTR I (Takara Bio, Otsu, Japan) and 
GeneArt Seamless Cloning and Assembly Kit (Invitro-
gen, Tokyo, Japan). Primers used for the cloning are listed 
in online Technical Appendix Table 2. We used genome 
DNAs of IFM 60814 (for wild-type [WT] gene) and IFM 
63240 (for mutated allele) as templates to clone the al-
leles. The resultant plasmids were pPTRI-erg6WT, pPTRI- 
hmg1WT, pPTRI-cyp51AWT, pPTRI-erg6A350T, pPTRI-
hmg1S269F, and pPTRI-cyp51AG448S, which we used for 
transformation of isolate IFM 60814. After selection with 
pyrithiamine, we verified the sequences of each gene of the 
candidate transformants by Sanger sequencing.
Results
Multiazole Resistant Strains from a Single Patient
We recovered a total of 19 A. fumigatus isolates from 1 pa-
tient on 9 testing dates during September 2011–May 2016 
(Tables 1, 2). Microsatellite analysis showed almost identi-
cal short tandem repeats across the isolates, derived from 
a genetically clonal background. The patient started treat-
ment with VRCZ after the first isolation of A. fumigatus in 
September 2011. Whereas the first isolate (IFM 60814) was 
susceptible to antifungal drugs including ITCZ, VRCZ, 
and PSCZ, later isolates showed resistance to the azoles 
(MICs: ITCZ, 4 to >8; VRCZ, 8 to >8; PSCZ, 4 to >8). 
By sequencing the cyp51A gene, we found amino acid 
substitution G448S IFM 62916 (second isolation date), 
IFM63248 (fourth isolation date), IFM63595 (sixth isola-
tion date), IFM63712 (seventh isolation date), IFM63713 
(seventh isolation date), and IFM64139 (eighth isolation 
date). These isolates were most likely resistant to VRCZ 
as a result of the G448S mutation, which has been reported 
to confer VRCZ resistance in A. fumigatus. However, the 
multiazole resistance mechanism in the isolates with no 
G448S mutation remained unknown. The growth of isolate 
IFM 62916 was markedly impaired with glucose minimal 
medium and potato dextrose agar, whereas the isolates 
from the third isolation date also showed a moderately de-
layed growth compared with those of the first strain (online 
Technical Appendix Figure 1).
Genome-Wide Sequence Comparison of  
Azole-Susceptible and Azole-Resistant Isolates
To gain insight into the multiazole resistance mechanism in 
the non-cyp51A strains, we sequenced the genomes of the 
isolates from the first (IFM 60814) and third (IFM 63240–
63243) testing dates by next-generation sequencing. Com-
pared with IFM 60814, IFM 63240–63243 commonly 
showed 7 nonsynonymous mutations, including 6 SNPs (4 
amino acid substitutions and 2 nonsense mutations, which 
generate termination codon) and a 1-bp deletion resulting 
in a frame shift of the protein (online Technical Appendix 
Table 2). The 6 genes with mutations included erg6, en-
coding sterol 24-C-methyltransferase and hmg1, encoding 
hydroxymethylglutaryl-CoA (HMG-CoA) reductase. The 
mutation of erg6 (A350T) resided in a Sterol_MT_C do-
main (PF08498) in the C-terminus, whereas the mutation 
of hmg1 (S269F) was located at the beginning of the sterol-
sensing domain (PF12349) (online Technical Appendix 
Figure 2). Because both of these genes are functionally re-
lated to the ergosterol biosynthesis pathway, we assumed 
that these mutations affect ergosterol biosynthesis and the 
consequential azole resistance in the strains.
We examined the rest of the isolates from the patient for 
mutations in the hmg1 and erg6 genes. Despite the presence 
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of A350T, we identified E49K in the erg6 gene in several 
isolates, whereas Hmg1 S269F existed in all isolates tested 
(Tables 1, 2). These results indicate that all of the isolates 
showing multiazole resistance had mutations in both hmg1 
and erg6 genes, regardless of the mutation in cyp51A gene.
Different Ergosterol Levels in  
Multiazole-Resistant Isolates
We investigated the phenotypes associated with the ergos-
terol biosynthesis pathway in IFM 63240, a representative 
of the isolate from the third testing day. Disk diffusion as-
say showed that this isolate was more sensitive to polyene 
drugs, amphotericin B, and nystatin, suggesting that ergos-
terol production might be differentially regulated (Figure 
1). The ergosterol content in the cells, measured by HPLC, 
showed significant increase (p = 0.0145) in the third set of 
isolates compared with the first isolate (Figure 2, panel A). 
At the same time, we found no differences between the first 
and third isolates regarding sensitivity to terbinafine, which 
interferes with the early stage of ergosterol biosynthesis, 
and fenpropimorph, which inhibits ergosterol biosynthe-
sis (data not shown). Of note, the isolate from the third set 
showed increased sensitivity to lovastatin, an inhibitor of 
HMG-CoA reductase (Figure 1).
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Figure 1. Growth inhibition by lovastatin and polyene drugs 
in azole-susceptible and azole-resistant Aspergillus fumigatus 
isolates from a patient in Japan. Growth inhibition tests were 
conducted by disk assay. IFM 60814 is a susceptible isolate 
identified on the first date of testing; IFM 63240 is a resistant 
isolate identified on the third date of testing, with mutations in 
hmg1. The results of repeated experiments are expressed as 
mean ± SD (error bars).
Figure 2. Total ergosterol content of azole-susceptible and 
azole-resistant Aspergillus fumigatus isolates in Japan. 
Ergosterol was quantified in the sets of IFM 60814, a 
susceptible isolate identified on the first date of testing, and 
IFM 63420, a resistant isolate identified on the third date 
of testing, both from 1 patient (A); and IFM 63666, IFM 
63768, and IFM 63772, all isolated from other patients in the 
same hospital (B). The results of repeated experiments are 
expressed as mean ± SD (error bars). The significance of total 
ergosterol content was determined by the Student  
t-test (unpaired, unequal variance). A p value <0.05 was 
considered significant.
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Evaluation of Mutant erg6 and hmg1 by Transformation
Considering the different level of ergosterol biosynthesis 
in the third set of isolates, we wanted to determine whether 
the mutation in erg6 and/or hmg1 genes was responsible for 
the phenotypes (i.e., sensitivity to polyenes and resistance 
to azoles). To address this question, we constructed the iso-
lates carrying these mutant alleles as well as the correspond-
ing wild-type gene by introducing erg6A350T or hmg1S269F 
into the first strain (hereafter designated as 1st+erg6A350T 
and 1st+hmg1S269F). These mutant alleles were ectopically 
expressed in the transformed strains. We also constructed 
the strain carrying cyp51AG448S (1st+cyp51AG448S) for veri-
fication of the role of the mutation in azole resistance as 
previously reported (27). The MICs for azoles were deter-
mined in these strains (Table 4), showing that introducing 
erg6A350T or hmg1S269F did not affect susceptibility to azoles, 
whereas the cyp51AG448S conferred resistance to VRCZ.
Mutations in erg6 and hmg1 in Other Non-cyp51A 
Azole-Resistant Isolates
We studied whether the other non-cyp51A azole-resistant 
isolates possess mutations in erg6 or hmg1. Over the past 
decade, we have collected clinical azole-resistant A. fumig-
atus strains in Japan: 4 non-cyp51A azole-resistant isolates 
(IFM 62140, IFM 64258, IFM 64303, and IFM 63768) 
showing a VRCZ MIC of >8 (Table 5). Each isolate was 
from a patient who had a history of treatment with VRCZ 
before isolation. Although IFM 64303 has no mutations in 
erg6 and hmg1 genes, the other 3 isolates possessed differ-
ent mutations in erg6 and/or hmg1. IFM 62140 had erg6A75S 
and hmg1F261_del, IFM 63768 had hmg1S269Y, and IFM 64258 
had erg6V206A and hmg1F390Y, which were different from the 
pattern observed in IFM 63240. These results suggested a 
potential link between azole resistance and the mutations 
in erg6 and hmg1 genes. Notably, IFM 63768 and IFM 
63240 had a mutation in Hmg1 at S269 in which serine 
was substituted by different amino acids (i.e., Hmg1S269Y 
and Hmg1S269F). To investigate the possibility that such 
mutations are just frequently occurring polymorphisms we 
sequenced erg6 and hmg1 in 16 azole-susceptible isolates. 
We did not find mutation in erg6, although 1 of the 16 
isolates, IFM 60901, had a hmg1H564Y mutation (Table 3). 
We did not find the mutations hmg1S269F/Y, hmg1F261_del, and 
hmg1F390Y in the azole-susceptible isolates. These results 
suggest that the mutations in erg6 and hmg1 found in the 
azole-resistant isolates are not mere polymorphisms in A. 
fumigatus but can be implicated in azole resistance.
Comparing Genome Sequences of Non-cyp51A  
Azole-Resistant Isolate and Corresponding Isolates
In our collection, an azole-susceptible isolate (IFM 63666) 
was isolated 2 months before isolation of azole-resistant 
IFM 63768 (hmg1S269Y) from the same patient. The 2 isolates 
shared the same short tandem repeats, indicating a clonal 
lineage. We then sequenced the genomes of IFM 63768 and 
IFM 63666. Comparing the genome sequences, we discov-
ered only 1 nonsynonymous mutation other than hmg1S269Y 
in IFM 63768, which was I395M in Afu4g04290 encod-
ing a putative histone H4 deacetylase protein. Although 
we could not see the effect of the mutation in Afu4g04290, 
this result supported the possibility that Hmg1S269Y is the 
determinant for azole resistance in this isolate. We com-
pared ergosterol levels in the cells between IFM63768 and 
IFM 63666 and found an increased amount in IFM 63768 
with hmg1S269Y (Figure 2, panel B). We isolated IFM 63772 
from the same patient in addition to these isolates, and it 
showed moderate resistance to VRCZ, resistance to PSCZ, 
and no mutations in erg6 and hmg1 (Table 5). The amount 
of ergosterol in IFM 63772 was comparable to that of IFM 
63666 (Figure 2, panel B).
Discussion
The emergence of drug-resistant fungal strains has been 
on the rise in recent years, leading to a serious situation. 
Azole-resistant strains occurring during the course of thera-
py have been increasingly reported all over the world since 
the early discovery of an ITCZ-resistant strain (5). Some 
studies have shown that there are many azole-resistant A. 
fumigatus strains without mutation in cyp51A gene, and the 
molecular mechanisms underlying resistance in the strains 
remain unstudied (28–30). This finding indicates that many 
unclear molecular mechanisms related to azole resistance 
still exist. 
In this study, we screened novel mutations conferring 
resistance by comparing the genomic sequences of suscep-
tible and resistant strains isolated from the same patient. 
We found mutations in hmg1 and erg6, encoding enzymes 
Hmg1 and Erg6, respectively, which are involved in 
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AMPH ITCZ VRCZ MCZ PSCZ 
1st+erg6WT cyp51A, erg6, +erg6WT, hmg1 <0.015 2 1 1–2 2 1–4 
1st+erg6A350T cyp51A, erg6, +erg6A350T, hmg1 <0.015 2 1 0.5–1 2 4 
1st+hmg1WT cyp51A, erg6, hmg1, +hmg1WT <0.015 2 1 1 2 1–4 
1st+hmg1S269F cyp51A, erg6, hmg1, +hmg1S269F <0.015 1–2 0.5–1 0.5 1–2 2–4 
1st+cyp51AWT cyp51A, +cyp51AWT, erg6, hmg1 <0.015 1–2 1 1–2 2–4 0.25–4 
1st+cyp51AG448S cyp51A, +cyp51AG448S, erg6, hmg1 <0.015 1–2 4 >8 4 4 
*AMPH, amphotericin B; ITCZ, itraconazole; MCFG, micafungin; MEC, minimal effective concentration; MCZ, miconazole; ND, not determined; PSCZ, 
posaconazole; STR, short tandem repeats; VRCZ, voriconazole.  
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ergosterol biosynthesis. Hmg1 is a HMG-CoA reductase 
that catalyzes reduction of HMG-CoA to mevalonic acid 
and acts as a rate-limiting enzyme in ergosterol biosyn-
thesis. Erg6 encodes sterol methyltransferase, which 
catalyzes the conversion of lanosterol to eburicol in A. 
fumigatus (26). The mutations of hmg1 we discovered 
were located in the sterol-sensing domain (SSD), respon-
sible for the function of this enzyme. Thus, the mutation 
(hmg1S269F) might affect ergosterol biosynthesis efficien-
cy. In fact, ergosterol levels in the strain bearing hmg1S269F 
or hmg1S269Y were increased, which led us to presume that 
such mutations altered the activity of Hmg1 and resulted 
in hyperaccumulation of ergosterol in the cells. Although 
further clarification is needed, one possibility is that larg-
er amounts of azole drugs are required to inhibit growth 
of the cells with an increased level of ergosterol. Among 
the non-cyp51A azole-resistant strains we studied, all 
the strains bearing mutation in hmg1 showed resistance 
to multiple azoles. This finding also supported the idea 
that the ergosterol level is a determinant for the resistance 
against any class of azoles.
Because Hmg1 acts as a rate-limiting enzyme, we in-
vestigated the phenotypes associated with ergosterol bio-
synthesis in the hmg1 mutated strain. Polyene drugs such as 
amphotericin B and nystatin bind to ergosterol in the plasma 
membrane, leading to cell death by promoting membrane 
leakage. Of note, the strain with mutation in Hmg1 was more 
sensitive to these polyene drugs, compared with the strains 
without the mutation, likely because the azole-resistant strain 
has more ergosterol in the cell membrane, and polyene can 
increasingly access ergosterol and damage the membrane. 
We also found that the azole-resistant strain with Hmg1 mu-
tation had increased susceptibility to lovastatin. Lovastatin is 
a competitive inhibitor of Hmg1, so the mutation may have 
increased the affinity to lovastatin. However, clarification for 
this will still be required in future studies.
Mutation of hmg1 has been reported in experiments 
designed to produce azole-resistant strains in the laboratory 
(31). In this study, the mutation in hmg1 was identified in 
clinical azole-resistant isolates. The mutation was discov-
ered in several isolates with different genetic backgrounds, 
which strongly suggested the importance of the mutation in 
azole resistance.
To analyze functions of the amino acid substitutions 
in Cyp51A, Hmg1, and Erg6 identified here, mutant al-
leles (cyp51AG448S, hmg1S269F, and erg6A350T) were ectopi-
cally expressed in susceptible strains. Introducing mutat-
ed cyp51AG448S conferred azole resistance in the host strain 
even in the presence of wild-type cyp51A. On the other 
hand, mutations in hmg1 and erg6 did not confer azole 
resistance when the wild type was present. The amino 
acid substitution of Hmg1 is present in SSD, which is a 
conserved motif of membrane proteins involved in sterol 
sensing and acts on feedback regulation of the enzymatic 
reaction (32). Therefore, the mutated Hmg1 may be im-
paired in the feedback regulation. In the strain express-
ing hmg1S269F, it is considered that wild-type hmg1 can 
receive feedback inhibition, and thus the strain did not 
accumulate ergosterol and did not alter azole susceptibil-
ity. All mutations of hmg1 found in this study are present 
in SSD, suggesting that mutations in SSD are important 
for conferring azole resistance.
In this study, we discovered novel genetic changes re-
lated to azole resistance. Several non-cyp51A azole-resis-
tant clinical isolates harbor the mutation in hmg1, which 
suggested that this possible resistance mechanism is preva-
lent in non-cyp51A strains. We proposed that multiazole 
drug resistance is imparted by a mutation in a protein other 
than the target protein of azole drugs. Future elucidation of 
the molecular mechanism of the hmg1 mutation will lead 
to a more complete understanding of the azole resistance 
mechanism in A. fumigatus.
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Table 5. Characteristics of Aspergillus fumigatus isolates from different patients in Japan* 
Isolate 





Gene with mutation 
 
STRs 
AMPH ITCZ VRCZ PSCZ cyp51A hmg1 erg6 3A 3B 3C 4A 4B 4C 
62140 K <0.015 2 4 8 2  – F261_del A75S  42 11 14 13 9 8 
64258 I <0.015 1 4 8 4  – F390Y V206A  26 14 17 5 11 10 
64303 T <0.015 2 2 8 –  – – –  34 18 22 10 11 11 
63666 C <0.015 1 1 2 1  – – –  29 13 15 10 9 5 
63768 C <0.015 1 8 >8 8  – S269Y –  29 13 15 10 9 5 
63772 C <0.015 1 2 4 8  – – –  29 13 15 10 9 5 
*AMPH, amphotericin B; IFM, Institute of Food Microbiology (now Medical Mycology Research Center), Chiba University, Chiba City, Japan; ITCZ, 
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